


Tumor treating fields sensitize trastuzumab resistant breast cancer



Supplementary Figure 1. The effect of trastuzumab-treatment on the viability of HER2-positive cell. A. TRZ inhibited HER2-positive cell viability in a dose-dependent manner. B. Cell viability was evaluated using MTT assay for Jimt1 and BT474 cells treated with the specified amounts of TRZ; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.